# Why Ozempic keeps wowing the world

Page: https://stenobird.com/podcast/abc-news-daily-504641/why-ozempic-keeps-wowing-the-world
Text version: https://stenobird.com/podcast/abc-news-daily-504641/why-ozempic-keeps-wowing-the-world.md
Podcast: [ABC News Daily](https://stenobird.com/podcast/abc-news-daily-504641)
Published: 2026-06-14T16:00:00+00:00
Episode link: https://www.abc.net.au/listen/programs/abc-news-daily/why-ozempic-keeps-wowing-the-world/106791344
Audio file: https://mediacore-live-production.akamaized.net/audio/02/lf/Z/b1.mp3
Processing state: not_requested
JSON: https://stenobird.com/v1/public/podcasts/abc-news-daily-504641/episodes/why-ozempic-keeps-wowing-the-world
Duration seconds: 861

## Resource

GLP-1 drugs were first approved to treat diabetes and then caused a frenzy when it was discovered they were great for weight loss. But now scientists are discovering the drugs that have brand names including Ozempic and Mounjaro might offer so much more, from reducing the risk of heart attack to treating kidney disease. Today, Doctor Paul Joyce, a pharmaceutical scientist at Adelaide University on how Ozempic is shaking things up, again. Featured: Doctor Paul Joyce, a pharmaceutical scientist at Adelaide University

## Actions

- request_transcript: `POST https://stenobird.com/v1/public/podcasts/abc-news-daily-504641/episodes/why-ozempic-keeps-wowing-the-world/transcription-requests` — Idempotently request low-priority transcript generation for this episode.
- read_markdown: `GET https://stenobird.com/podcast/abc-news-daily-504641/why-ozempic-keeps-wowing-the-world.md` — Read the agent-friendly Markdown representation of this episode resource.

A page view does not enqueue transcription. Agents should invoke `request_transcript` explicitly when they need this episode processed.

## Transcript

Full transcripts are not published on public pages unless there is a clear rights basis.